Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany
Peter Mohr(Elbe Kliniken Stade-Buxtehude), Michael Weichenthal(Christian-Albrechts-Universität zu Kiel), Jochen Utikal(German Cancer Research Center), Chalid Assaf(MSH Medical School Hamburg – University of Applied Sciences and Medical University), Rudolf Herbst(Helios Klinikum Erfurt), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Claudia Pföhler(Saarland University), Sebastian Haferkamp(University Hospital Regensburg), Katharina C. Kähler(Christian-Albrechts-Universität zu Kiel), Dirk Schadendorf(National Center for Tumor Diseases), Marc Bender(Elbe Kliniken Stade-Buxtehude), Friedegund Meier(National Center for Tumor Diseases), Clemens Krepler(Merck & Co., Inc., Rahway, NJ, USA (United States)), Sheenu Chandwani(Merck & Co., Inc., Rahway, NJ, USA (United States)), Axel Hauschild(University Hospital Schleswig-Holstein), Julia Welzel(University Hospital Augsburg), Ruixuan Jiang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Thomas Eigentler(University Children's Hospital Tübingen), Carola Berking(Universitätsklinikum Erlangen), Selma Ugurel(Klinikum Bielefeld), Jessica C. Hassel(German Cancer Research Center), Gaston Schley(Helios Hospital Schwerin), Carmen Loquai(Johannes Gutenberg University Mainz), Anja Rudolph(Institut für Qualität im Management (Germany)), Alexander Kreuter(HELIOS St. Elisabeth Klinik Oberhausen), Ulrike Leiter(University of Tübingen), M. Schiavone, Emilie Scherrer(Seagen (United States)), Jens Ulrich, Carsten Weishaupt(University Hospital Münster), Imke Grimmelmann(Medizinische Hochschule Hannover), Patrick Terheyden(University Hospital Schleswig-Holstein)
Cited by 13
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k